Kapoor NS, Banks KC. Should multi-gene panel testing replace limited BRCA1/2 testing? A review of genetic testing for hereditary breast and ovarian cancers. World J Surg Proced 2016; 6(1): 13-18 [DOI: 10.5412/wjsp.v6.i1.13]
Corresponding Author of This Article
Nimmi S Kapoor, MD, Director, Department of Surgical Oncology, Breastlink, 230 S. Main Street, Suite 100, Orange, CA 92868, United States. nimmi.kapoor@breastlink.com
Research Domain of This Article
Genetics & Heredity
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nimmi S Kapoor, Department of Surgical Oncology, Breastlink, Orange, CA 92868, United States
Kimberly C Banks, Medical Science Liason, Guardant Health, Redwood City, CA 94063, United States
ORCID number: $[AuthorORCIDs]
Author contributions: Kapoor NS designed, wrote, and edited this manuscript; Banks KC wrote and edited this manuscript.
Conflict-of-interest statement: Kapoor NS has received honoraria for serving as a speaker for Ambry Genetics and Banks KC was previously employed by Ambry Genetics.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Nimmi S Kapoor, MD, Director, Department of Surgical Oncology, Breastlink, 230 S. Main Street, Suite 100, Orange, CA 92868, United States. nimmi.kapoor@breastlink.com
Telephone: +1-714-6193308 Fax: +1-714-5410450
Received: August 22, 2015 Peer-review started: August 23, 2015 First decision: October 27, 2015 Revised: December 12, 2015 Accepted: January 5, 2016 Article in press: January 7, 2016 Published online: March 28, 2016 Processing time: 216 Days and 1.5 Hours
Abstract
Clinical testing of patients for hereditary breast and ovarian cancer syndromes began in the mid-1990s with the identification of the BRCA1 and BRCA2 genes. Since then, mutations in dozens of other genes have been correlated to increased breast, ovarian, and other cancer risk. The following decades of data collection and patient advocacy allowed for improvements in medical, legal, social, and ethical advances in genetic testing. Technological advances have made it possible to sequence multiple genes at once in a panel to give patients a more thorough evaluation of their personal cancer risk. Panel testing increases the detection of mutations that lead to increased risk of breast, ovarian, and other cancers and can better guide individualized screening measures compared to limited BRCA testing alone. At the same time, multi-gene panel testing is more time-and cost-efficient. While the clinical application of panel testing is in its infancy, many problems arise such as lack of guidelines for management of newly identified gene mutations, high rates of variants of uncertain significance, and limited ability to screen for some cancers. Through on-going concerted efforts of pooled data collection and analysis, it is likely that the benefits of multi-gene panel testing will outweigh the risks in the near future.
Core tip: Evaluating multiple genes in a panel test has clear advantages over BRCA1/2 testing including a greater likelihood of identifying patients with actionable pathogenic mutations, improved efficiency over sequential testing, and lower overall cost. At the same time, panel testing comes with limitations; most notably a lack of clear management guidelines for mutations in moderate penetrance genes and limited evidence-based clinical validity. As more information is gathered on these moderate- and low-penetrance gene mutations, the ability to guide clinical decisions for patients will continue to improve.
Citation: Kapoor NS, Banks KC. Should multi-gene panel testing replace limited BRCA1/2 testing? A review of genetic testing for hereditary breast and ovarian cancers. World J Surg Proced 2016; 6(1): 13-18
The first hereditary susceptibility gene associated with breast cancer risk was identified in 1994 and called BRCA1[1,2]. At that time, there were approximately 182000 cases of breast cancer diagnosed annually in the United States[3] and a growing concern to identify causative factors for a highly prevalent disease. Shortly thereafter in 1995, the BRCA2 gene was identified and these two genes, BRCA1 and BRCA2 (BRCA1/2), began to play an important role in evaluating newly diagnosed breast cancer patients and others with high-risk family histories.
Initially, when clinical testing of BRCA1/2 mutations began in 1996, there were many uncertainties and criticisms: Data to demonstrate outcomes and benefit of proposed management was still being gathered, directive guidelines did not exist, and understanding of the expanding phenotype and variable penetrance was still occurring. The rate of inconclusive results was higher, time to receive results was closer to two months, patient concern about genetic discrimination was much more pronounced, and protective legislation specific to genetic test results was limited. Furthermore, the long-term psychological impact of genetic testing results was yet unknown.
It is now well-documented that germline BRCA1/2 mutations significantly increase risk for breast, ovarian, and male breast cancer as well as moderately increase risk for prostate and pancreatic cancer[4-6]. Established national guidelines identify which clinical histories warrant BRCA1/2 genetic testing and how to manage patients who carry BRCA1/2 mutations, specifically high-risk surveillance and risk-reducing surgical options[7]. BRCA1/2 genetic testing is now routinely covered by insurance companies in patients with defined clinical histories, the rate of inconclusive results is less than 5%, and results are returned in approximately two weeks. Ultimately, a federal law was passed called Genetic Information Nondiscrimination Act “GINA” of 2008 to prevent medical insurance companies and employers from discriminating against individuals on the basis of their genetic information[8]. Fortunately, initial data has shown that no significant long-term psychological and emotional consequences occur as a result of genetic testing[9].
Many breast surgeons incorporate BRCA1/2 testing into the initial work-up of newly diagnosed breast cancer patients who meet testing criteria to guide surgical decisions. Family members of affected individuals or other high-risk patients can also be easily referred for cancer genetic counseling for testing and preventive intervention strategies. The high prevalence of BRCA1/2 mutations among male breast cancer patients and ovarian cancer patients has led to recommendations that any patient with one of these diseases obtain BRCA1/2 testing[7]. In the last few years, testing criteria have also expanded to include pancreatic cancer and high-grade prostate cancer indications[7].
RECENT SHIFTS
Of hereditary breast cancers, only 30%-50% is attributed to mutations in BRCA1 and BRCA2 genes[10-12]. Over several decades of research, additional genetic mutations in numerous other genes have been implicated in breast and ovarian cancer risk. There are now over 20 genes and hundreds of mutations that have been implicated in the development of breast and/or ovarian cancer (Table 1)[12-14].
Table 1 List of select genes that can be found on multi-gene panels and associated cancer risks.
Breast, ovarian, osteosarcomas, brain tumors, colorectal, other gastrointestinal sites
Traditionally, testing patients or those at risk for hereditary breast and ovarian cancer risk-began with evaluating BRCA1/2. If results were negative, additional testing was offered, often several weeks to months later, only if the patient met certain criteria for additional genetic syndromes. Numerous advances from scientific technology to legislation to public awareness and media, have shifted this testing paradigm.
Technological advances in DNA sequencing have come to what some have termed a “tipping point” in the advancement of genetic evaluation and discovery of new mutations related to hereditary cancer risk[15]. In place of more tedious methods of DNA sequencing using Sanger sequencing techniques, massively parallel DNA sequencing using Next Generation Sequencing (NGS) allows multiple genes to be evaluated at once.
With NGS, came the opportunity to offer panel testing, or evaluating numerous genes at once rather than in sequence. Panel testing decreased the turn-over-time for results while minimizing the cost of the test[10,13]. Even with panel testing, however, there were still restrictions with including BRCA1/2 testing on a panel due to patents held by the founding company on evaluating these genes for almost 20 years. It was not until a 2013 Supreme Court ruling of Association for Molecular Pathology v. Myriad Genetics that many of these patents that restricted BRCA1/2 testing became invalidated[16]. Since then, multi-gene panels offered by numerous genetic testing companies were able to include BRCA1/2 in their panels and offer patients comprehensive testing upfront[17].
Another equally important event that occurred to influence hereditary genetic testing patterns was the public disclosure of the highly acclaimed actress Angelina Jolie’s BRCA1 mutation status in 2013. When Jolie explained her decision to choose prophylactic bilateral mastectomy and oophorectomy due to her BRCA1 mutation, mainstream media brought public awareness to the importance of hereditary genetic testing and as a result, there became a surge in numbers of patients undergoing testing[18]. While numbers referred for testing have more than doubled in some locations, the majority of referrals have been found to be appropriate and for qualified candidates[18].
NEWER DATA
With this shift in testing, the clinical impact of multi-gene panel testing has become apparent. Prior to inclusion of BRCA1/2 in panels, LaDuca et al[19] evaluated over 2000 patients who underwent multi-gene panel testing with 14-21 genes (excluding BRCA1/2) between March 2012 and May 2013. Overall, 8.3% of patients were found to carry pathogenic mutations, ranging from 7.2%-9.6% depending on the number of genes evaluated. Of patients who were deemed to be high risk for hereditary breast and ovarian cancer and underwent a “breast” panel with genes implicated in breast cancer pathogenesis, 10.9% of patients were found to carry pathogenic mutations. The genes found to be mutated most frequently in this cohort of high-risk patients included PALB2, CHEK2, and ATM.
Similarly, Tung et al[20] evaluated over 2000 high-risk patients who underwent a NGS multi-gene panel testing with 25 genes including BRCA1/2. Of patients who underwent panel testing with BRCA1/2, 9.3% were found to carry a BRCA1/2 mutation and an additional 4.2% of patients carried non-BRCA mutations again with the most frequent gene mutations in PALB2, CHEK2, and ATM. Smaller studies have also shown the benefit of panel testing[14,21-23].
We have demonstrated that multi-gene panel testing nearly doubles the pathogenic mutation detection rate in patients with increased risk of hereditary breast and/or ovarian cancer when compared to limited BRCA1/2 testing alone in a cohort of 966 high-risk patients[21]. Likewise, a French group used their own NGS panel of 27 genes to evaluate 708 high-risk patients and found a 15.4% mutation detection rate[14]. Mutations in BRCA1/2 accounted for 59% of these genetic alterations in the French study, while 41% were non-BRCA genes, again most frequently in PALB2, CHEK2, and ATM genes.
When patients undergo panel testing with multiple genes, there is an increased detection of pathogenic mutations, but there is also increased detection of DNA variants of uncertain significance (VUS). Depending on the number of genes in a panel and the patients who are tested, VUS rates from panel testing have been reported to range from 6.7%-41.7%[19-21]. The VUS rate for any given gene will be highest initially as data starts to accumulate, then will decrease over time[19]. Nonetheless, BRCA1/2 testing is still associated with a VUS rate of approximately 4%[21].
BENEFITS
In order for a new testing method to replace an established algorithm, a substantial benefit should be possible with limited consequences. There are a number of obvious advantages of multi-gene panel testing over limited BRCA1/2 testing. Panel testing not only provides patients with more information about their hereditary risk by increasing the detection of pathogenic mutations, but it also identifies actionable mutations for which patients can choose to increase surveillance of high risk cancers, initiate chemoprevention, or even undergo prophylactic surgery to remove a potential at-risk organ site.
Carrying a BRCA1/2 mutation leads to a lifetime risk of breast cancer up to 85% and a lifetime risk of developing ovarian cancer between 15%-60%[4-6]. Increased surveillance with breast MRI can detect breast cancers at earliest stages for these patients, while prophylactic bilateral mastectomy decreases this risk by over 90% and prophylactic bilateral salpingo-oophorectomy minimizes the risk of both ovarian and breast cancer[24,25]. Similarly, patients with mutations in non-BRCA genes that are associated with increased risk of breast cancer, such as PALB2, CHEK2, and ATM, may also benefit from increased screening with breast MRI. Other patients with these non-BRCA gene mutations, especially those with a strong family history of breast cancer or who carry particularly penetrant gene mutations may even benefit from prophylactic mastectomies[26-31].
In addition to identifying genes associated with breast and/or ovarian cancer risk, panel testing identifies genes with cancer risk in other organ sites (Table 1). Mutations in the PTEN gene, for example, confer a risk of breast, thyroid, and endometrial cancer. Patients with PTEN mutations and the related Cowden syndrome are recommended to not only have increased breast cancer surveillance, but annual thyroid ultrasounds and endometrial evaluations as well[7]. On the other hand, MSH2 mutations are implicated in Lynch syndrome, which is characterized by increased risk of early onset colon, uterine, and ovarian cancers[32]. For these patients, consideration of hysterectomy and oophorectomy and increased frequency of colonoscopies should be included in counseling. Multi-gene panel testing can help direct focused screening in high risk patients and even enable risk-reducing interventions.
Other benefits of panel testing over sequential testing include the ability to test for genes that a patient might not normally be considered for. This is especially true for more rare gene mutations that are typically associated with particular family inheritance patterns or traits such as Li Fraumeni syndrome or Cowden Syndrome[33,34]. With panel testing, these rare mutation carriers can be more readily identified in patients with limited or unknown family history.
Fortunately, NGS allows for multi-gene panel testing to be both efficient and cost-effective[13,23,35]. Rather than thousands of dollars for only BRCA1/2 testing, dozens of genes can now be sequenced at once for a fraction of the cost.
LIMITATIONS AND CONCERNS
While panel testing increases the diagnostic yield by up to 50% compared to BRCA1/2 testing alone, sometimes the pathogenic mutation identified is in a gene for which there is limited data as to the cancer risks and cancer spectrum so patient management recommendations will not be available. National Comprehensive Cancer Network guidelines currently provide detailed recommendations for a handful of well-characterized, highly-penetrant genes (BRCA1, BRCA2, PTEN, TP53, CDH1, and STK11) and also provide breast and ovarian management considerations for some of the genes commonly identified by panel testing (ATM, CHEK2, and PALB2)[7]. Detailed recommendations, however, accounting for the other cancer risks associated with these genes and recommendations for management of patients with mutations in less-characterized genes do not yet exist. It is also possible that mutations in moderate/intermediate-risk genes may not entirely explain a personal and/or family history of cancer; the role of gene/gene and gene/environment interactions could influence the manifestation of a gene mutation and/or cause phenocopies in the family (people who do not carry a known familial mutation but develop a cancer associated with the familial gene mutation). In addition, others have argued that there is a lack of clinical validity due to limited data sets that estimate cancer risk for many of the genes found on panels[36]. Clearly larger population and family-based studies will be needed to provide the best risk-estimates for appropriate counseling for the more rare gene mutations. Given this, management recommendations for patients (and their family members) with mutations in less-characterized genes need to take into account what is known about the specific gene as well as the personal and family clinical history[21].
With the identification of cancer risk outside of breast, colon, and ovarian cancer, comes the question of how to screen for and/or prevent rare cancers that associated with specific gene mutations (Table 1). This dilemma is not specific to the “newer” genes included on many panels. Patients with a BRCA1/2 gene mutation and family history of pancreatic cancer are counseled that they likely have an increased risk for pancreatic cancer, but screening for early-detection of pancreatic cancer is not well-established and only recommended within the scope of a clinical trial[37]. Patients found to carry a TP53 gene mutation are informed that they have a significantly elevated risk for multiple types of cancers, some of which we have screening modalities and guidelines for but others which do not[7]. On the other hand, patients with a CDH1 gene mutation can have up to a 70% risk of gastric cancer by age 80 and may be recommended to consider prophylactic total gastrectomy[38]. As with targeted BRCA1/2 or TP53 testing, patients undergoing panel testing need to be informed of the benefits, limitations, and possible implications of testing, including limited screening and prevention options for certain cancers.
Another limitation with panel testing is the higher rate of inconclusive (variant of uncertain significance) results. Similar to the early days of BRCA1/2 genetic testing when VUS rates were higher, clinicians ordering panels for their patients must be aware of the higher possibility of identifying a VUS and make empiric management recommendations based on the personal and family clinical history when such a result is received[19-22]. An inconclusive result can cause patient (and clinician) anxiety about future cancer risks and potential risk for family members. Patients with VUS results can contribute to research specific to their gene variant and participate in national registries such as the Prospective Registry of Multiplex Testing. Often, however, facilitation of patient participation in such research falls to the managing busy clinician. As additional data is accumulated, VUS results are ultimately re-classified to either benign or deleterious, often years later, and the original ordering clinician receives the reclassification report that they must then act upon.
Lastly, as with any emerging technology, NGS and multi-gene panel tests are currently without established insurance guidelines for payment reimbursement. Without a panel-specific current procedural terminology (CPT) code, billing for panel tests is not as straightforward as BRCA1/2 or Lynch testing for which gene-specific CPT codes exist. Obtaining authorization for BRCA1/2 testing is fairly simple, while obtaining authorization for panel testing may require more work from the clinicians’ office, although some laboratories will perform insurance authorization services to support the process.
CONCLUSION
Evaluating patients at risk for hereditary breast and ovarian cancer syndromes has transformed in a short period of time. Mutations in BRCA1/2 genes are still the most common gene mutations accounting for inherited cancer risk, however numerous other genes have been added to the spectrum of hereditary cancer risk. Evaluating multiple genes in a panel test has clear advantages over BRCA1/2 testing including a greater likelihood of identifying patients with actionable pathogenic mutations, improved efficiency over sequential testing, and lower overall cost. At the same time, panel testing comes with limitations; most notably a lack of clear management guidelines for mutations in moderate penetrance genes and limited evidence-based clinical validity. As more information is gathered on these moderate- and low-penetrance gene mutations and VUS through national efforts, our ability to guide clinical decisions for our patients will continue to improve. In the interim, thoughtful application of existing guidelines for gene mutations with cancer risk profiles similar to genes with established guidelines can be applied in the management of patients with mutations in some of these newer genes.
Footnotes
P- Reviewer: Butow P, Chung YJ S- Editor: Qi Y L- Editor: A E- Editor: Jiao XK
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.Am J Hum Genet. 2003;72:1117-1130.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 2571][Cited by in F6Publishing: 2495][Article Influence: 118.8][Reference Citation Analysis (0)]
Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.JAMA. 1996;275:1885-1892.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 435][Cited by in F6Publishing: 406][Article Influence: 14.5][Reference Citation Analysis (0)]
Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, Brault B, Fouillet R, Goardon N, Letac O. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.Eur J Hum Genet. 2014;22:1305-1313.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 175][Cited by in F6Publishing: 184][Article Influence: 18.4][Reference Citation Analysis (0)]
Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.Cancer. 2015;121:25-33.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 304][Cited by in F6Publishing: 324][Article Influence: 32.4][Reference Citation Analysis (0)]
Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG, Banks KC. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.Ann Surg Oncol. 2015;22:3282-3288.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 77][Cited by in F6Publishing: 86][Article Influence: 9.6][Reference Citation Analysis (0)]
Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Tan M, Meijers-Heijboer HE, Klijn JG, Seynaeve C. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.Ann Surg Oncol. 2007;14:3335-3344.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 118][Cited by in F6Publishing: 109][Article Influence: 6.4][Reference Citation Analysis (0)]
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.JAMA. 2010;304:967-975.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1040][Cited by in F6Publishing: 1040][Article Influence: 74.3][Reference Citation Analysis (0)]
Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds.Cancer Res. 1988;48:5358-5362.
[PubMed] [DOI][Cited in This Article: ]
